EMA Authorised: Steglujan (ertugliflozin l-pyroglutamic acid;sitagliptin phosphate monohydrate) — Merck Sharp & Dohme B.V.

View source ↗

Summary

EMA authorised Steglujan, a fixed-dose combination tablet of ertugliflozin and sitagliptin, for type 2 diabetes mellitus in the EU, issued to Merck Sharp & Dohm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Ertugliflozin (ertugliflozin)
• STEGLUJAN (ERTUGLIFLOZIN AND SITAGLIPTIN)
• Sitagliptin (sitagliptin)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Merck Sharp & Dohme B.V.. Decision date: 21/11/2025